Chronic Lymphocytic Leukemia

CLINICAL_TRIALS trial_result · 2025-06-03

Clinical Trial Update: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL [Phase 1]

Phase I study of ONO-4685 as monotherapy to evaluate tolerability and safety in relapsed or refractory T cell lymphoma and chronic lymphocyt…

CLINICAL_TRIALS trial_result · 2025-05-25

Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]

Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.

CLINICAL_TRIALS research · 2025-05-22

Clinical Trial Update: A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. [Phase 1]

Phase 1 trial evaluating a personalized neoantigen cancer vaccine in treatment-naïve, asymptomatic IGHV-unmutated chronic lymphocytic leukem…

CLINICAL_TRIALS withdrawal · 2025-05-22

Clinical Trial Update: Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL [Phase 2]

A Phase 2 trial studying Copanlisib in combination with Ibrutinib or Acalabrutinib for relapsed/refractory Chronic Lymphocytic Leukemia has …

FDA approval · 2025-05-22

FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)

FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…

CLINICAL_TRIALS trial_result · 2025-05-21

Clinical Trial Update: MEOI and HRQoL in CLL Patients Treated With BTKis

A clinical trial evaluating MEOI and health-related quality of life in chronic lymphocytic leukemia patients treated with BTK inhibitors has…

CLINICAL_TRIALS withdrawal · 2025-05-16

Clinical Trial Update: A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A clinical trial evaluating a time-limited use of Ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdra…

CLINICAL_TRIALS other · 2025-05-16

Clinical Trial Update: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies [Phase 1]

Phase 1 clinical trial evaluating Genetically Engineered Anti-CD19/CD20/CD22 CAR T-cells for relapsed or refractory lymphoid malignancies; c…

CLINICAL_TRIALS trial_result · 2025-05-13

Clinical Trial Update: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib [Phase 1]

This Phase 1 trial evaluated VAY736 in combination with ibrutinib in patients with chronic lymphocytic leukemia who were on ibrutinib. The s…

CLINICAL_TRIALS research · 2025-05-01

Clinical Trial Update: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies [Phase 1, Phase 2]

IDP-121 is being studied in a Phase 1/2 trial for relapsed/refractory hematologic malignancies and is currently recruiting.

CLINICAL_TRIALS research · 2025-04-30

Clinical Trial Update: Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)

An ongoing clinical trial evaluating acalabrutinib in chronic lymphocytic leukemia patients taking direct oral anticoagulants; the study is …

CLINICAL_TRIALS trial_result · 2025-04-29

Clinical Trial Update: Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma [Phase 1]

Phase 1 clinical trial evaluating pentostatin, bendamustine, and ofatumumab for chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma…

CLINICAL_TRIALS trial_result · 2025-04-24

Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]

Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …

CLINICAL_TRIALS trial_result · 2025-04-17

Clinical Trial Update: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation [Phase 3]

Phase 3 trial comparing venetoclax plus obinutuzumab against FCR/BR in previously untreated chronic lymphocytic leukemia has completed and p…

CLINICAL_TRIALS trial_result · 2025-04-16

Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]

Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…

CLINICAL_TRIALS trial_result · 2025-04-16

Clinical Trial Update: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL [Phase 1, Phase 2]

A clinical trial is evaluating APG2575 as both a single agent and in combination therapy for relapsed/refractory chronic lymphocytic leukemi…

CLINICAL_TRIALS research · 2025-04-16

Clinical Trial Update: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies [Phase 1]

Phase 1 study of APG-2575 by Ascentage Pharma for chronic lymphocytic leukemia and non-Hodgkin lymphoma is currently active but not recruiti…

CLINICAL_TRIALS trial_result · 2025-04-10

Clinical Trial Update: A Study Of The Selective PKC-β Inhibitor MS- 553 [Phase 1, Phase 2]

A Phase 1/2 study of the selective PKC-β inhibitor MS-553 in chronic lymphocytic leukemia, small lymphocytic lymphoma, and aggressive lympho…

CLINICAL_TRIALS research · 2025-04-10

Clinical Trial Update: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL [Phase 1]

This clinical trial update describes a Phase 1 study of APG-2575, studied as a single agent or in combination with other therapies for chron…

CLINICAL_TRIALS research · 2025-04-10

Clinical Trial Update: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry

Clinical trial update indicates ongoing recruitment for the AGMT Austrian CLL Registry, a registry study involving chronic lymphocytic leuke…

CLINICAL_TRIALS trial_result · 2025-04-06

Clinical Trial Update: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [Phase 2]

A Phase 2 trial evaluating α/β+-T lymphocyte-depleted donor grafts from HLA-mismatched donors in multiple hematologic malignancies was termi…

EMA approval · 2025-04-03

EMA Authorised: MabThera (rituximab) — Roche Registration GmbH

EMA authorised MabThera (rituximab) for multiple indications including Non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphocytic l…

CLINICAL_TRIALS trial_result · 2025-03-28

Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]

Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.

CLINICAL_TRIALS research · 2025-03-21

Clinical Trial Update: Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) [NA]

A CARTIER clinical trial is evaluating cardiovascular prevention strategies in elderly cancer patients and is currently recruiting.

CLINICAL_TRIALS trial_result · 2025-03-20

Clinical Trial Update: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies [Phase 1, Phase 2]

Acalabrutinib is being evaluated in Phase 1/2 studies in Chinese adults with relapsed or refractory mantle cell lymphoma and chronic lymphoc…

Top drugs studied for this disease